Hsp90 inhibitors exert therapeutic activity in type VII collagen–induced EBA. Mice were immunized with 60 μg of GST-mCVIIC and disease was allowed to progress until moderate average clinical scores (primarily ≥ 2) were observed, at which time vehicle vs 17-DMAG (30 mg/kg 3 times a week; A) or vehicle vs TCBL-145 (3 mg/kg daily; B) was administered over a 6-week treatment period. Data are presented as the average clinical scores defined as the percentage of body surface area affected by skin lesions at the end of the treatment period. Values are means ± SEM of ≥ 6 mice per group. *P < .05. (C) Representative clinical presentations of vehicle- and 17-DMAG–treated mice at the end of the treatment period. Vehicle-treated mice had erythema, erosions, and crusts predominantly located on the ears and around the eyes, whereas 17-DMAG–injected mice presented with significantly less severe disease.